Symbols / INMB Stock $1.39 +0.72% INmune Bio Inc.
INMB (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Ratings
Current target
$1.39
Low
$4.00
High
$9.00
Mean
$7.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | up | LUCID CAPITAL MARKETS | Neutral → Buy | $9 |
| 2025-07-02 | main | Maxim Group | Buy → Buy | $8 |
| 2025-07-01 | down | BTIG | Buy → Neutral | — |
| 2025-07-01 | down | Scotiabank | Sector Outperform → Sector Underperform | $1 |
| 2025-02-13 | main | Maxim Group | Buy → Buy | $30 |
| 2025-02-11 | main | Scotiabank | Sector Outperform → Sector Outperform | $23 |
| 2023-06-01 | init | Baird | — → Outperform | $16 |
| 2022-05-24 | main | BTIG | — → Buy | $14 |
| 2022-05-24 | down | B. Riley Securities | Buy → Neutral | $7 |
| 2022-01-24 | main | B. Riley Securities | — → Buy | $20 |
| 2021-04-21 | init | B. Riley Securities | — → Buy | $29 |
| 2020-11-09 | main | HC Wainwright & Co. | — → Buy | $15 |
| 2020-09-01 | init | BTIG | — → Buy | $23 |
| 2020-07-15 | main | HC Wainwright & Co. | — → Buy | $20 |
| 2020-05-15 | reit | HC Wainwright & Co. | — → Buy | $8 |
| 2020-03-12 | main | HC Wainwright & Co. | — → Buy | $8 |
| 2019-12-19 | init | Roth Capital | — → Buy | $13 |
| 2019-08-21 | init | HC Wainwright & Co. | — → Buy | $12 |
| 2019-03-19 | init | Maxim Group | — → Buy | — |
- INMB stock rises pre-market – what did the FDA say about its Alzheimer’s trial? - MSN Sun, 26 Apr 2026 17
- INmune Bio will discuss 2025 results and corporate update March 30 - Stock Titan ue, 24 Mar 2026 07
- INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance hu, 06 Nov 2025 08
- INMB 260515 1.00P (INMB260515P1000) Stock Options Chain | Quotes & News - Moomoo ue, 21 Apr 2026 13
- INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial? - Stocktwits hu, 12 Feb 2026 12
- INMB Stock Receives Major Upgrade from Lucid Capital Markets | I - GuruFocus Wed, 11 Mar 2026 07
- Can INmune Bio (INMB) Stock Beat the Market | Price at $1.25, Up 3.72% - Trending Volume Leaders - Cổng thông tin điện tử Tỉnh Sơn La Mon, 06 Apr 2026 07
- INmune Bio Inc. (INMB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Sat, 18 Apr 2026 00
- Expanded equity plan and board elections on deck at INmune Bio (NASDAQ: INMB) 2026 meeting - Stock Titan hu, 23 Apr 2026 20
- INmune Bio stock falls after new Alzheimer’s trial data - Investing.com Mon, 01 Dec 2025 08
- INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely - Yahoo Finance Wed, 01 Apr 2026 07
- Alzheimer’s trial signal and rare skin disease cell therapy at INmune Bio - Stock Titan ue, 27 Jan 2026 08
- INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance Mon, 08 Sep 2025 07
- INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial - MSN Sat, 17 Jan 2026 11
- INmune targets first UK filing for rare skin disease therapy by mid-summer - Stock Titan Mon, 30 Mar 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.05
+257.14%
|
0.01
-90.97%
|
0.15
-58.56%
|
0.37
|
| Operating Revenue |
|
0.05
+257.14%
|
0.01
-90.97%
|
0.15
-58.56%
|
0.37
|
| Operating Expense |
|
30.92
-27.50%
|
42.65
+42.66%
|
29.90
+13.57%
|
26.32
|
| Research And Development |
|
20.66
-37.71%
|
33.17
+63.60%
|
20.27
+18.78%
|
17.07
|
| Selling General And Administration |
|
10.26
+8.19%
|
9.48
-1.45%
|
9.62
+3.94%
|
9.26
|
| General And Administrative Expense |
|
10.26
+8.19%
|
9.48
-1.45%
|
9.62
+3.94%
|
9.26
|
| Other Gand A |
|
10.26
+8.19%
|
9.48
-1.45%
|
9.62
+3.94%
|
9.26
|
| Total Expenses |
|
30.92
-27.50%
|
42.65
+42.66%
|
29.90
+13.57%
|
26.32
|
| Operating Income |
|
-30.87
+27.60%
|
-42.63
-43.35%
|
-29.74
-14.60%
|
-25.95
|
| Total Operating Income As Reported |
|
-47.38
-11.14%
|
-42.63
-43.35%
|
-29.74
-14.60%
|
-25.95
|
| EBITDA |
|
-30.79
+27.79%
|
-42.63
-43.35%
|
-29.74
-14.60%
|
-25.95
|
| Normalized EBITDA |
|
-14.27
+66.53%
|
-42.63
-43.35%
|
-29.74
-14.60%
|
-25.95
|
| Reconciled Depreciation |
|
0.08
|
0.00
|
—
|
—
|
| EBIT |
|
-30.87
+27.60%
|
-42.63
-43.35%
|
-29.74
-14.60%
|
-25.95
|
| Total Unusual Items |
|
-16.51
|
0.00
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
-16.51
|
0.00
|
—
|
—
|
| Special Income Charges |
|
-16.51
|
0.00
|
—
|
—
|
| Impairment Of Capital Assets |
|
16.51
|
0.00
|
—
|
—
|
| Net Income |
|
-45.93
-9.15%
|
-42.08
-40.24%
|
-30.01
-9.92%
|
-27.30
|
| Pretax Income |
|
-45.93
-9.15%
|
-42.08
-40.24%
|
-30.01
-9.92%
|
-27.30
|
| Other Income Expense |
|
-15.06
-2824.05%
|
0.55
+307.12%
|
-0.27
+80.19%
|
-1.35
|
| Other Non Operating Income Expenses |
|
1.45
+162.21%
|
0.55
+307.12%
|
-0.27
+80.19%
|
-1.35
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-45.93
-9.15%
|
-42.08
-40.24%
|
-30.01
-9.92%
|
-27.30
|
| Net Income From Continuing Operation Net Minority Interest |
|
-45.93
-9.15%
|
-42.08
-40.24%
|
-30.01
-9.92%
|
-27.30
|
| Net Income From Continuing And Discontinued Operation |
|
-45.93
-9.15%
|
-42.08
-40.24%
|
-30.01
-9.92%
|
-27.30
|
| Net Income Continuous Operations |
|
-45.93
-9.15%
|
-42.08
-40.24%
|
-30.01
-9.92%
|
-27.30
|
| Normalized Income |
|
-29.42
+30.09%
|
-42.08
-40.24%
|
-30.01
-9.92%
|
-27.30
|
| Net Income Common Stockholders |
|
-45.93
-9.15%
|
-42.08
-40.24%
|
-30.01
-9.92%
|
-27.30
|
| Diluted EPS |
|
—
|
-2.11
-26.35%
|
-1.67
-9.87%
|
-1.52
|
| Basic EPS |
|
—
|
-2.11
-26.35%
|
-1.67
-9.87%
|
-1.52
|
| Basic Average Shares |
|
—
|
19.94
+10.92%
|
17.98
+0.30%
|
17.93
|
| Diluted Average Shares |
|
—
|
19.94
+10.92%
|
17.98
+0.30%
|
17.93
|
| Diluted NI Availto Com Stockholders |
|
-45.93
-9.15%
|
-42.08
-40.24%
|
-30.01
-9.92%
|
-27.30
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
32.35
-18.23%
|
39.56
-30.59%
|
57.00
-30.31%
|
81.80
|
| Current Assets |
|
29.89
+31.88%
|
22.66
-43.26%
|
39.94
-38.24%
|
64.67
|
| Cash Cash Equivalents And Short Term Investments |
|
24.75
+18.30%
|
20.92
-41.64%
|
35.85
-31.26%
|
52.15
|
| Cash And Cash Equivalents |
|
24.75
+18.30%
|
20.92
-41.64%
|
35.85
-31.26%
|
52.15
|
| Cash Financial |
|
—
|
—
|
—
|
—
|
| Receivables |
|
4.54
+222.29%
|
1.41
-42.30%
|
2.44
-71.14%
|
8.46
|
| Taxes Receivable |
|
4.54
+222.29%
|
1.41
-42.30%
|
2.44
-71.14%
|
8.46
|
| Prepaid Assets |
|
—
|
0.00
-100.00%
|
0.14
+317.65%
|
0.03
|
| Other Current Assets |
|
0.59
+79.76%
|
0.33
-78.08%
|
1.51
-62.50%
|
4.03
|
| Total Non Current Assets |
|
2.46
-85.42%
|
16.90
-0.93%
|
17.06
-0.36%
|
17.12
|
| Net PPE |
|
1.87
+508.79%
|
0.31
-25.85%
|
0.41
-18.34%
|
0.51
|
| Gross PPE |
|
1.87
+508.79%
|
0.31
-25.85%
|
0.41
-18.34%
|
0.51
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
0.91
+197.72%
|
0.31
-25.85%
|
0.41
-18.34%
|
0.51
|
| Other Properties |
|
0.95
|
—
|
—
|
—
|
| Goodwill And Other Intangible Assets |
|
0.00
-100.00%
|
16.51
+0.00%
|
16.51
+0.00%
|
16.51
|
| Other Intangible Assets |
|
—
|
16.51
+0.00%
|
16.51
+0.00%
|
16.51
|
| Other Non Current Assets |
|
0.59
+653.16%
|
0.08
-39.69%
|
0.13
+32.32%
|
0.10
|
| Total Liabilities Net Minority Interest |
|
8.83
+18.25%
|
7.46
-60.42%
|
18.86
-13.04%
|
21.69
|
| Current Liabilities |
|
8.42
+16.55%
|
7.22
-60.89%
|
18.46
+69.12%
|
10.92
|
| Payables And Accrued Expenses |
|
7.79
+18.72%
|
6.56
-17.29%
|
7.94
+52.18%
|
5.21
|
| Payables |
|
7.79
+18.72%
|
6.56
-17.29%
|
7.94
+52.18%
|
5.21
|
| Accounts Payable |
|
7.79
+18.72%
|
6.56
-17.29%
|
7.94
+52.18%
|
5.21
|
| Current Debt And Capital Lease Obligation |
|
0.62
+345.00%
|
0.14
-98.61%
|
10.04
+97.37%
|
5.09
|
| Current Debt |
|
—
|
—
|
9.92
+98.42%
|
5.00
|
| Other Current Borrowings |
|
—
|
—
|
9.92
+98.42%
|
5.00
|
| Current Capital Lease Obligation |
|
0.62
+345.00%
|
0.14
+17.65%
|
0.12
+36.78%
|
0.09
|
| Current Deferred Liabilities |
|
0.00
-100.00%
|
0.52
+5.73%
|
0.49
-20.62%
|
0.62
|
| Total Non Current Liabilities Net Minority Interest |
|
0.41
+68.44%
|
0.24
-38.54%
|
0.40
-96.31%
|
10.77
|
| Long Term Debt And Capital Lease Obligation |
|
0.41
+68.44%
|
0.24
-38.54%
|
0.40
-96.12%
|
10.22
|
| Long Term Debt |
|
—
|
—
|
—
|
9.70
|
| Long Term Capital Lease Obligation |
|
0.41
+68.44%
|
0.24
-38.54%
|
0.40
-24.52%
|
0.53
|
| Stockholders Equity |
|
23.52
-26.71%
|
32.10
-15.84%
|
38.14
-36.54%
|
60.10
|
| Common Stock Equity |
|
23.52
-26.71%
|
32.10
-15.84%
|
38.14
-36.54%
|
60.10
|
| Capital Stock |
|
0.03
+22.73%
|
0.02
-97.31%
|
0.82
+4438.89%
|
0.02
|
| Common Stock |
|
0.03
+22.73%
|
0.02
-97.31%
|
0.82
+4438.89%
|
0.02
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
26.59
+19.32%
|
22.28
+24.12%
|
17.95
+0.03%
|
17.95
|
| Ordinary Shares Number |
|
26.59
+19.32%
|
22.28
+24.12%
|
17.95
+0.03%
|
17.95
|
| Additional Paid In Capital |
|
233.27
+19.17%
|
195.75
+23.01%
|
159.14
+4.84%
|
151.80
|
| Retained Earnings |
|
-209.04
-28.16%
|
-163.10
-34.77%
|
-121.02
-32.97%
|
-91.01
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.74
-28.17%
|
-0.57
+28.04%
|
-0.80
-14.31%
|
-0.70
|
| Other Equity Adjustments |
|
-0.74
-28.17%
|
-0.57
+28.04%
|
-0.80
-14.31%
|
-0.70
|
| Total Equity Gross Minority Interest |
|
23.52
-26.71%
|
32.10
-15.84%
|
38.14
-36.54%
|
60.10
|
| Total Capitalization |
|
23.52
-26.71%
|
32.10
-15.84%
|
38.14
-45.36%
|
69.80
|
| Working Capital |
|
21.47
+39.05%
|
15.44
-28.10%
|
21.48
-60.05%
|
53.76
|
| Invested Capital |
|
23.52
-26.71%
|
32.10
-33.21%
|
48.06
-35.75%
|
74.80
|
| Total Debt |
|
1.03
+169.27%
|
0.38
-96.32%
|
10.44
-31.83%
|
15.31
|
| Capital Lease Obligations |
|
1.03
+169.27%
|
0.38
-25.58%
|
0.52
-15.82%
|
0.61
|
| Net Tangible Assets |
|
23.52
+50.96%
|
15.58
-27.94%
|
21.62
-50.39%
|
43.59
|
| Tangible Book Value |
|
23.52
+50.96%
|
15.58
-27.94%
|
21.62
-50.39%
|
43.59
|
| Non Current Accrued Expenses |
|
—
|
—
|
0.00
-100.00%
|
0.55
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-22.58
+32.31%
|
-33.36
-178.47%
|
-11.98
+47.19%
|
-22.69
|
| Cash Flow From Continuing Operating Activities |
|
-22.58
+32.31%
|
-33.36
-178.47%
|
-11.98
+47.19%
|
-22.69
|
| Net Income From Continuing Operations |
|
-45.93
-9.15%
|
-42.08
-40.24%
|
-30.01
-9.92%
|
-27.30
|
| Depreciation Amortization Depletion |
|
0.08
|
0.00
|
—
|
—
|
| Depreciation |
|
0.08
|
0.00
|
—
|
—
|
| Depreciation And Amortization |
|
0.08
|
0.00
|
—
|
—
|
| Other Non Cash Items |
|
-0.63
-892.41%
|
0.08
-64.73%
|
0.22
-6.28%
|
0.24
|
| Stock Based Compensation |
|
9.91
+30.31%
|
7.61
+3.22%
|
7.37
+3.06%
|
7.15
|
| Asset Impairment Charge |
|
16.51
|
0.00
|
0.00
-100.00%
|
0.09
|
| Change In Working Capital |
|
-2.53
-344.07%
|
1.04
-90.06%
|
10.44
+464.39%
|
-2.86
|
| Change In Receivables |
|
-3.13
-403.19%
|
1.03
-82.84%
|
6.02
+303.55%
|
-2.96
|
| Change In Prepaid Assets |
|
-0.26
-119.98%
|
1.32
-45.16%
|
2.41
+236.18%
|
-1.77
|
| Change In Payables And Accrued Expense |
|
1.85
+235.20%
|
-1.37
-163.20%
|
2.17
+23.84%
|
1.75
|
| Change In Accrued Expense |
|
—
|
0.00
+100.00%
|
-0.55
-256.70%
|
0.35
|
| Change In Payable |
|
1.85
+235.20%
|
-1.37
-150.42%
|
2.72
+94.08%
|
1.40
|
| Change In Account Payable |
|
1.85
+235.20%
|
-1.37
-150.42%
|
2.72
+94.08%
|
1.40
|
| Change In Other Working Capital |
|
-0.52
-1946.43%
|
0.03
+122.05%
|
-0.13
-189.44%
|
0.14
|
| Change In Other Current Assets |
|
-0.52
-1092.31%
|
0.05
+262.50%
|
-0.03
|
0.00
|
| Change In Other Current Liabilities |
|
0.04
+272.00%
|
-0.03
-525.00%
|
-0.00
+87.88%
|
-0.03
|
| Investing Cash Flow |
|
-1.04
|
0.00
|
—
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
-1.04
|
0.00
|
—
|
0.00
|
| Net PPE Purchase And Sale |
|
-1.04
|
0.00
|
—
|
—
|
| Purchase Of PPE |
|
-1.04
|
0.00
|
—
|
—
|
| Capital Expenditure |
|
-1.04
|
—
|
—
|
—
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of Intangibles |
|
—
|
—
|
—
|
0.00
|
| Financing Cash Flow |
|
27.61
+51.62%
|
18.21
+531.03%
|
-4.22
-679.56%
|
0.73
|
| Cash Flow From Continuing Financing Activities |
|
27.61
+51.62%
|
18.21
+531.03%
|
-4.22
-679.56%
|
0.73
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-10.00
-100.00%
|
-5.00
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-10.00
-100.00%
|
-5.00
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-10.00
-100.00%
|
-5.00
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
+100.00%
|
-10.00
-100.00%
|
-5.00
|
0.00
|
| Net Common Stock Issuance |
|
27.54
-0.88%
|
27.79
+3485.68%
|
0.78
+10.87%
|
0.70
|
| Common Stock Payments |
|
—
|
—
|
—
|
—
|
| Repurchase Of Capital Stock |
|
—
|
—
|
—
|
—
|
| Proceeds From Stock Option Exercised |
|
0.07
-83.89%
|
0.42
|
0.00
-100.00%
|
0.03
|
| Changes In Cash |
|
3.99
+126.32%
|
-15.15
+6.51%
|
-16.20
+26.20%
|
-21.96
|
| Effect Of Exchange Rate Changes |
|
-0.16
-170.98%
|
0.22
+324.00%
|
-0.10
+85.71%
|
-0.70
|
| Beginning Cash Position |
|
20.92
-41.64%
|
35.85
-31.26%
|
52.15
-30.29%
|
74.81
|
| End Cash Position |
|
24.75
+18.30%
|
20.92
-41.64%
|
35.85
-31.26%
|
52.15
|
| Free Cash Flow |
|
-23.62
+29.19%
|
-33.36
-178.47%
|
-11.98
+47.19%
|
-22.69
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
1.69
-4.95%
|
1.78
+29.59%
|
1.37
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock Issuance |
|
27.54
-0.88%
|
27.79
+3485.68%
|
0.78
+10.87%
|
0.70
|
| Issuance Of Capital Stock |
|
27.54
-0.88%
|
27.79
+3485.68%
|
0.78
+10.87%
|
0.70
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-30 View
- 8-K2026-02-27 View
- 8-K2026-02-23 View
- 8-K2026-02-19 View
- 8-K2026-02-13 View
- 8-K2026-01-27 View
- 8-K2025-12-23 View
- 8-K2025-12-19 View
- 8-K2025-12-10 View
- 8-K2025-12-08 View
- 8-K2025-12-05 View
- 8-K2025-12-03 View
- 42025-12-02 View
- 42025-12-02 View
- 42025-12-02 View
- 42025-12-02 View
- 42025-12-02 View
- 42025-12-02 View
- 42025-12-02 View
- 8-K2025-11-28 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|